Constitutive systemic expression of IL-1Ra or soluble TNF receptor by genetically modified hematopoietic cells suppresses LPS induction of IL-6 and IL-10

Gene Therapy

Volumn 4, Issue 3, 1997, Pages 252-257

  Doughty, L A ^a   Patrene, K D ^a   Evans, C H ^a   Boggs, S S ^a   Robbins, P D ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Gene therapy; IL 1Ra; Interleukin 10; Interleukin 6; sTNF receptor

Indexed keywords

BETA GALACTOSIDASE; IMMUNOMODULATING AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; CELL SUBPOPULATION; CONTROLLED STUDY; EXPRESSION VECTOR; GENE EXPRESSION; GENE TRANSFER; HEMATOPOIETIC STEM CELL; IMMUNOMODULATION; IMMUNOPHENOTYPING; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; RECEPTOR GENE; RETROVIRUS; T LYMPHOCYTE SUBPOPULATION;

EID: 0030969720     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300387     Document Type: Article

References (34)

1. Liles WC, Van Voorhis WC. Nomenclature and biologic significance of cytokines involved in inflammation and the host immune response. J Infect Dis 1995; 172: 1573-1580.
2. Harris MC et al. Cytokine elevation in critically ill infants with sepsis and necrotizing enterocolitis. J Pediatr 1994; 124: 105-111.
3. Sullivan, JS et al. Correlation of plasma cytokine elevations with mortality rate in children with sepsis. J Pediatr 1992; 120: 510-515.
4. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119: 771-778.
5. Damas PD et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992; 215: 356-362.
6. de Waal Malefyt R et al. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209-1220.
7. Howard M, Muchamuel T, Andrade S, Menon S. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 1993 177: 1205-1208.
8. Gerard C et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993; 177: 547-550.
9. Willems FA et al. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol 1994; 24: 1007-1009.
10. Buelens CF et al. Interleukin-10 differentially regulates B7-1 (CD80) and B7-2 (CD86) expression on human peripheral blood dendritic cells. Eur J Immunol 1995; 25: 2668-2672.
11. Suzuki T et al. Viral interleukin-10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors. J Exp Med 1995; 182: 477-486.
12. Gomez-Jimenez JMC et al. Interleukin-10 and the monocyte/macrophage-induced inflammatory response in septic shock. J Infect Dis 1995; 171: 472-475.
13. Marchant A et al. Clinical and biological significance of interleukin-10 plasma levels in patients with septic shock. J Clin Immunol 1995; 15: 266-273.
14. Doughty L. The IL-10 response in pediatric sepsis and organ failure. Crit Care Med 1996; 24: A32.
15. Dinarello CA, Thompson RC. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 1991; 12: 404-410.
16. Bemelmans MHA, Gouma DJ, Buurman WA. LPS-induced sTNF-receptor release in vivo in a murine model. J Immunol 1993; 151: 5554-5562.
17. Mohler KM et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993, 151: 1548-1561.
18. Hannum CH et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1991; 343: 336-340.
19. Lesslauer WH et al. Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol 1991; 21: 2883-2886.
20. Mengozzi M, Bertini R, Sironi M, Ghezzi P. Inhibition by interleukin 1 receptor antagonist of in vivo activities of interleukin 1 in mice. Lymphokine Cytokine Res 1991; 10: 405-407.
21. Alexander RH et al. A recombinant human receptor antoagonist to interleukin 1 improves survival after lethal endotoxemia in mice. J Exp Med 1991; 173: 1029-1032.
22. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effects of endotoxin. Science 1985; 229. 869-871.
23. Tracey KJ et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662-664.
24. Fong Y et al. Antibodies to cachectin/TNF reduce interleukin-1 and interleukin-6 appearance during lethal bacteremia. J Exp Med 1989; 170: 1627-1633.
25. Barsig JS et al. Lipopolysaccharide-induced interleukin-10 in mice: role of endogenous tumor necrosis factor-alpha. Eur J Immunol 1995; 25: 2888-2893.
26. Marchant A et al. Interleukin-10 controls interferon-gamma and tumor necrosis factor production during experimental endotoxemia. Eur J Immunol 1994; 24: 1167-1171.
27. Evans CH, Robbins PD. Prospects for treating arthritis by gene therapy (editorial). J Rheum 1994; 21: 779-782.
28. Evans CH, Robbins PD. The interleukin-1 receptor antagonist and its delivery by gene transfer (review). Receptor 1994; 4: 9-15.
29. Bandara G et al. Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci USA 1993; 90: 10764-10768.
30. Bandara G et al. Gene transfer to synoviocytes: prospects for gene treatment of arthritis (review). DNA Cell Biol 1992; 11: 227-231.
31. Hung GL et al. Suppression of intraarticular responses to interleukin-1 by transfer of the interleukin-1 receptor antagonist gene to synovium. Gene Therapy 1993; 1: 64-69.
32. Boggs SS et al. Prolonged systemic expression of human IL-1 receptor antagonist (hIL-1ra) in mice reconstituted with hematopoietic cells transduced with a retrovirus carrying the hIL-1ra cDNA. Gene Therapy 1995; 2: 632-638.
33. Chernajovsky Y et al. Inhibition of transfer of collagen induced arthritis into SCID mice by gene transfer of spleen cells with retroviruses expressing soluble human tumor necrosis factor receptor. Gene Therapy 1995; 2: 731-735.
34. Boggs SS, Schwartz GN. Increased lethality after endotoxin in old or leukemic AKR mice. Proc Soc Exp Biol Med 1978, 157: 424-429.